Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

Sponsor
David Sanchez Garcia
Study ID
NCT05467514
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus

Study Details

The aim of the trail is investigate the effect of liraglutide 1.8mg as add-on to insulin for 6 months on carotid intima media thickness and cardiovascular risk factors in subjects with type 1 diabetes mellitus.

Key Dates

Start date
Jul 1, 2022
Status verified
Feb 2023
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus

Primary Outcome Measure

To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus. [ Time Frame: Baseline and 6 months ]

Related Studies